Is Exicure, Inc. overvalued or undervalued?

As of 9 February 2024, Exicure, Inc. has moved from a valuation grade of very attractive to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as evidenced by its P/B ratio of 10.08 and negative metrics such as an EV to EBITDA of -13.68 and an ROE of -41.72%.
When compared to peers, Exicure's valuation metrics are less favorable; for instance, Benitec Biopharma, Inc. has an EV to EBITDA of -10.1454, and Monopar Therapeutics, Inc. stands at -8.7189. The stark contrast in performance is further underscored by Exicure's poor stock performance, with a year-to-date decline of 52.45% compared to a modest 2.44% gain in the S&P 500. Overall, the financial ratios and peer comparisons suggest that Exicure, Inc. is significantly overvalued in the current market.